vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and SOLAREDGE TECHNOLOGIES, INC. (SEDG). Click either name above to swap in a different company.
SOLAREDGE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($335.4M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 70.9%). Over the past eight quarters, SOLAREDGE TECHNOLOGIES, INC.'s revenue compounded faster (28.1% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
SolarEdge Technologies, Inc. is an Israeli company that developed a DC optimized inverter system.
ESPR vs SEDG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $335.4M |
| Net Profit | — | $-132.1M |
| Gross Margin | — | 22.2% |
| Operating Margin | 50.6% | -14.4% |
| Net Margin | — | -39.4% |
| Revenue YoY | 143.7% | 70.9% |
| Net Profit YoY | — | 54.0% |
| EPS (diluted) | $0.32 | $-2.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $335.4M | ||
| Q3 25 | $87.3M | $340.2M | ||
| Q2 25 | $82.4M | $289.4M | ||
| Q1 25 | $65.0M | $219.5M | ||
| Q4 24 | $69.1M | $196.2M | ||
| Q3 24 | $51.6M | $235.4M | ||
| Q2 24 | $73.8M | $265.4M | ||
| Q1 24 | $137.7M | $204.4M |
| Q4 25 | — | $-132.1M | ||
| Q3 25 | $-31.3M | $-50.1M | ||
| Q2 25 | $-12.7M | $-124.7M | ||
| Q1 25 | $-40.5M | $-98.5M | ||
| Q4 24 | — | $-287.4M | ||
| Q3 24 | $-29.5M | $-1.2B | ||
| Q2 24 | $-61.9M | $-130.8M | ||
| Q1 24 | $61.0M | $-157.3M |
| Q4 25 | — | 22.2% | ||
| Q3 25 | — | 21.2% | ||
| Q2 25 | — | 11.1% | ||
| Q1 25 | — | 8.0% | ||
| Q4 24 | — | -57.2% | ||
| Q3 24 | — | -309.1% | ||
| Q2 24 | — | -4.1% | ||
| Q1 24 | — | -12.8% |
| Q4 25 | 50.6% | -14.4% | ||
| Q3 25 | -11.4% | -10.3% | ||
| Q2 25 | 8.6% | -39.9% | ||
| Q1 25 | -34.0% | -46.8% | ||
| Q4 24 | -6.4% | -134.4% | ||
| Q3 24 | -31.0% | -471.8% | ||
| Q2 24 | 3.5% | -60.4% | ||
| Q1 24 | 52.5% | -85.0% |
| Q4 25 | — | -39.4% | ||
| Q3 25 | -35.9% | -14.7% | ||
| Q2 25 | -15.4% | -43.1% | ||
| Q1 25 | -62.2% | -44.9% | ||
| Q4 24 | — | -146.5% | ||
| Q3 24 | -57.2% | -522.8% | ||
| Q2 24 | -83.9% | -49.3% | ||
| Q1 24 | 44.3% | -77.0% |
| Q4 25 | $0.32 | $-2.21 | ||
| Q3 25 | $-0.16 | $-0.84 | ||
| Q2 25 | $-0.06 | $-2.13 | ||
| Q1 25 | $-0.21 | $-1.70 | ||
| Q4 24 | $-0.14 | $-5.00 | ||
| Q3 24 | $-0.15 | $-21.58 | ||
| Q2 24 | $-0.33 | $-2.31 | ||
| Q1 24 | $0.34 | $-2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $493.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $427.5M |
| Total Assets | $465.9M | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $493.2M | ||
| Q3 25 | $92.4M | $498.6M | ||
| Q2 25 | $86.1M | $758.0M | ||
| Q1 25 | $114.6M | $651.6M | ||
| Q4 24 | $144.8M | $585.9M | ||
| Q3 24 | $144.7M | $678.8M | ||
| Q2 24 | $189.3M | $689.8M | ||
| Q1 24 | $226.6M | $680.6M |
| Q4 25 | $-302.0M | $427.5M | ||
| Q3 25 | $-451.4M | $479.8M | ||
| Q2 25 | $-433.5M | $513.2M | ||
| Q1 25 | $-426.2M | $594.2M | ||
| Q4 24 | $-388.7M | $658.3M | ||
| Q3 24 | $-370.2M | $930.9M | ||
| Q2 24 | $-344.2M | $2.1B | ||
| Q1 24 | $-294.3M | $2.2B |
| Q4 25 | $465.9M | $2.2B | ||
| Q3 25 | $364.0M | $2.2B | ||
| Q2 25 | $347.1M | $2.5B | ||
| Q1 25 | $324.0M | $2.5B | ||
| Q4 24 | $343.8M | $2.6B | ||
| Q3 24 | $314.1M | $2.8B | ||
| Q2 24 | $352.3M | $3.9B | ||
| Q1 24 | $373.1M | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $52.6M |
| Free Cash FlowOCF − Capex | — | $43.3M |
| FCF MarginFCF / Revenue | — | 12.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $80.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $52.6M | ||
| Q3 25 | $-4.3M | $25.6M | ||
| Q2 25 | $-31.4M | $-7.8M | ||
| Q1 25 | $-22.6M | $33.8M | ||
| Q4 24 | $-35.0M | $37.8M | ||
| Q3 24 | $-35.3M | $-89.3M | ||
| Q2 24 | $-7.2M | $-44.8M | ||
| Q1 24 | $53.8M | $-217.0M |
| Q4 25 | — | $43.3M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | — | $-9.1M | ||
| Q1 25 | — | $23.7M | ||
| Q4 24 | — | $25.5M | ||
| Q3 24 | $-35.5M | $-136.7M | ||
| Q2 24 | $-7.3M | $-67.0M | ||
| Q1 24 | $53.8M | $-243.4M |
| Q4 25 | — | 12.9% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | — | -3.1% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -68.7% | -58.1% | ||
| Q2 24 | -9.9% | -25.2% | ||
| Q1 24 | 39.0% | -119.1% |
| Q4 25 | 0.0% | 2.8% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 4.6% | ||
| Q4 24 | 0.0% | 6.2% | ||
| Q3 24 | 0.3% | 20.1% | ||
| Q2 24 | 0.1% | 8.4% | ||
| Q1 24 | 0.1% | 12.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SEDG
| Other | $197.7M | 59% |
| Europe Except Netherlands | $99.4M | 30% |
| Others | $38.2M | 11% |
